Baroreflex Sensitivity as a Cardiac and Arrhythmia Mortality Risk Stratifier

The last two decades have provided clear evidence for the tight and casual relation existing between arrhythmic mortality and the autonomic nervous system, particularly with imbalances characterized by decreases in vagal and/or increases in sympathetic activity. A series of compelling experimental results has represented the driving force for the clinical evaluation of the potential prognostic value of baroreflex sensitivity (BBS), a measure that can provide information on the capability to augment vagal activity. This article reviews the methodology more commonly used to quantify the clinical evaluation of this parameter, and then focuses on the key clinical studies highlighting those performed in postmyocardial infarction patients. Among them the most informative is ATRAMI, a multicenter prospective study involving almost 1300 patients. The main conclusion is that both heart rate variability and BRS are strong and independent risk factors for post-infarction mortality, thus demonstrating the clinical usefulness of autonomic markers.     

A Fractally Coated, 1.3 mm2 High Impedance Pacing Electrode

Minimizing the geometric surface area of pacing electrodes increases impedance and reduces the current drain during stimulation, provided that voltage (pulse-width) thresholds remain unchanged. This may be feasible by coating the electrode surface to increase the capacity of the electrode tissue interface and to diminish polarization. Ten unipolar, tined leads with a surface area of 1.3 mm² and a “fractal” coating of Iridium (Biotronik SD-V137) were implanted in the ventricle, and electrogram amplitude (unfiltered), slew-rate, pacing threshold (0.5 ms), and impedance (2.5 V; 0.5 ms) were measured by the 5311 PSA (Medtronic). On days 0, 2, 5, 10, 28, 90, 180, 360 postimplant, sensing threshold (up to 7.0 mV, measuring range 1–14 mV on day 360 only) and the strength duration curve (0.5–4.0 V; 0.03–1.5 ms; steps: 0.5 V; 0.01 ms, respectively) were determined, the minimum charge delivered per pulse (charge threshold), and the impedance were taken from pacemaker telemetry (Intermedics 294–03). Data were compared with those of an earlier series of 20 unipolar, tined TIR-leads (Biotronik) with a surface area of 10 mm² and a “fractal” coating of titanium nitride. With the model SD-V137 versus TIR, intraoperative electrogram amplitudes were 15.1 ± 6.1 versus 14.4 ± 3.9 mV(NS), slew rates 3.45 ± 1.57 versus 1.94 ± 1.06 V/s (P < 0. 05), pacing thresholds 0.16 ± 0.05 versus 0.52 ± 0.15 V (P < 0.01) and impedance measurements 1,136 ±175 versus 441 ± 73 Ω (P < 0.0001), respectively. During follow-up, sensing thresholds were the same with both leads. Differences in pulse width thresholds lost its significance on day 28 but resumed on day 360 (SD-V137: 0.08 ± 0.04 ms; TIR: 0.16 ± 0.06 ms at 2.5 V; P < 0.01). With an electrode surface of 1.3 mm², charge per pulse and impedance consistently differed from control, beingO.15 ± 0.15 versus 0. 66 ± 0. 20 μC (P < 0.001) and 1,344 ± 376 versus 538 ± 79 Ω, respectively, one year after implantation (P < 0.0001). In summary, “fractally” coated small surface electrodes do not compromise sensing; by more than doubling impedance against controls they offer pacing thresholds (mainly in terms of charge) that are significantly lower than with the reference electrode.     

Intrathoracic Pressure as a Tourniquet Technic to Tamponade Bleeding Esophageal Varices

The authors' report observations on 79 cases of esophagovariceal bleeding in which ten cases were subjected to an intrathoracic tourniquet maneuver of increasing intrathoracic pressure. All esophagovariceal bleeding ceased following the maneuver. An established maneuver safety limit (holding mean transmural CVP to no higher than 4.0 cm H2O) insured cardiac output maintenance and guaranteed against maneuver-generated morbidity. The authors conclude the cessation of the bleeding from esophageal varices observed is the combined result of tourniquet-tamponade by direct venous air compression on the bleeding varices as well as general esophageal compression.     

Studies of Alpha-2-Adrenoceptor Function in Abstinent Alcoholics

Hormonal, haemodynamic and subjective psychological responses to the intravenous infusion of clonidine were investigated in nine male alcoholics who had been abstinent for 5 weeks, and were compared with those of nine healthy controls. The growth hormone response to clonidine was significantly blunted in the abstinent alcoholics. Both baseline cortisol levels and the clonidine-induced cortisol decrease were significantly greater in the alcoholics than in controls. Blood pressure, pulse rate and psychological responses to clonidine were similar in both groups. These results indicate that some aspects of alpha-2-adrenoceptor sensitivity are persistently abnormal in alcoholics at least 5 weeks into abstinence.     

Malposition of Transvenous Pacing Lead in the Left Ventricle

Malposition of pacemaker leads has been described in several locations but rarely in the left ventricle. The incidence and clinical course of this pacemaker complication are unknown. We describe clinical, electrocardiographic, chest X ray, and echocardiographic findings in four patients in whom the transvenous pacing lead was inadvertendy placed through the interatrial septum and mitral valve into the left ventricle, in these patients, lead misplacement was not recognized at the time of implantation and lead malposition was diagnosed a mean of 2 years later. All four patients had right bundle branch block configuration paced complexes. In retrospect, chest X rays suggested atypical lead position in all, but the initial posterioranterior and lateral chest X rays were misinterpreted and contributed to the delay in diagnosis. When lead misplacement in the left ventricle was considered it was confirmed by two-dimensional echocardiography. One patient subsequently presented with a stroke and the remainder were diagnosed when they presented with other unrelated problems. Pacing thresholds were normal at the time of implantation and behaved normally during follow-up. The patient presenting with stroke was anticoagulated and the other three have been managed expectantly without anticoagulafion. Diagnosis of left ventricular lead malposition is not difficult but requires a high index of suspicion. A 12-lead ECC and posterior-anterior and lateral chest X rays after implantation can be diagnostic. Patients with pacing lead in the left ventricle may remain asymptomatic with normal lead function during long-term follow-up. Anticoagulation should be considered when this problem comes to attention for the first time during follow-up.     

Comparison of acute haemodynamic effects of dopexamine hydrochloride, dobutamine and sodium nitroprusside in chronic heart failure

Dopexamine hydrochloride (Dopacard®) is a new syntheticcatecholamine compound, which possesses potent ß2-adrenergicand D A 1-dopaminergic agonistic properties. It is free of a-adrenergicactivity, has no ß1-adrenergic activity and is lesspotent at D A2-dopaminergic receptors than dopamine. In thepresent study the acute haemodynamic effects of dopexamine hydrochloridewere compared to those of dobutamine and nitroprusside in 12patients with idiopathic congestive cardiomyopathy in an opencrossover study. With dopexamine hydrochloride, there were dose-dependentincreases from control in cardiac output and stroke volume,decreases in blood pressure, right and left atrial pressure,systemic vascular resistance and pulmonary vascular resistanceand little change in heart rate. Similar effects were seen withnitroprusside, apart from a marked increase in heart rate, andwith dobutamine, except that systolic aortic blood pressureincreased and there was no change in diastolic or mean pressureor pulmonary artery systolic pressure. In general, dopexamine hydrochloride produced effects betweenthose produced by the other two treatments. This suggests thatdopexamine with its combined vasodilator and inotropic actionhas a desirable cardiovascular profile with advantages overthe ß1-receptor aganist dobutamine and the pure vasodilatorsodium nitroprusside.     

Clinical Efficacy and Safety of the New Cardioverter Defibrillator Systems

Clinical efficacy and safety of two new third-generation implantable cardioverter defibrillators (ICD) were studied in 38 patients with ventricular tachycardia (VT) or fibrillation (VF). There were 31 patients with coronary disease, three patients with right ventricular dysplasia, one patient with dilated cardiomyopathy, and three patients with valvular disease. Twenty-four patients (group I) received an ICD with monophasic (Ventak PRx 1700, CPI) and 14 patients (group II) with biphasic shocks (Cadence V 100, Ventritex). Intraoperatively, the mean defibrillation threshold was significantly lower in group II than in group I, both in patients with induced VT (group I 11.0 ± 6.3 joules: group N 5.8 ± 1.3 joules) (P < O.01) and induced VF (group I 17.5 ± 4.6 joules; group II 9.6 ± 5.2 joules) (P < O.O1). During the mean follow-up of 12 ± 7 months four patients (11%) died. 865 arrhythmia events (AE) occurred and were terminated by ATP (671 VTs, 78%). Acceleration of VTs was observed in 28 AE (3%) and ATP was unable to interrupt 58 AE (7%). ICD shocks were delivered as a first therapy in 108 AE (13%).